MX380191B - Combinaciones de modalidades para el tratamiento de la diabetes. - Google Patents

Combinaciones de modalidades para el tratamiento de la diabetes.

Info

Publication number
MX380191B
MX380191B MX2015000238A MX2015000238A MX380191B MX 380191 B MX380191 B MX 380191B MX 2015000238 A MX2015000238 A MX 2015000238A MX 2015000238 A MX2015000238 A MX 2015000238A MX 380191 B MX380191 B MX 380191B
Authority
MX
Mexico
Prior art keywords
diabetes
type
modalities
combinations
treatment
Prior art date
Application number
MX2015000238A
Other languages
English (en)
Other versions
MX2015000238A (es
Inventor
Tihamer Orban
Original Assignee
Orban Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orban Biotech Llc filed Critical Orban Biotech Llc
Publication of MX2015000238A publication Critical patent/MX2015000238A/es
Publication of MX380191B publication Critical patent/MX380191B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La presente invención se refiere a un método para tratar, prevenir, o retrasar la progresión de la diabetes mellitus tipo 1 al administrar una cantidad eficaz de una composición de proteína de fusión que comprende un antagonista de coestímulo de célula T y una porción de una molécula de inmunoglobulina y una cantidad eficaz de un autoantígeno de diabetes tipo 1. El método incluye, por ejemplo, administrar una molécula de antígeno 4 asociado al linfocito T citotóxico (CTLA4, por sus siglas en inglés) y un autoantígeno de diabetes tipo 1. Las composiciones farmacéuticas también se proporcionan en el presente documento.
MX2015000238A 2012-06-27 2013-06-27 Combinaciones de modalidades para el tratamiento de la diabetes. MX380191B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/534,571 US8735359B2 (en) 2012-05-24 2012-06-27 Combinations of modalities for the treatment of diabetes
PCT/US2013/048247 WO2014004866A1 (en) 2012-06-27 2013-06-27 Combinations of modalities for the treatment of diabetes

Publications (2)

Publication Number Publication Date
MX2015000238A MX2015000238A (es) 2015-08-14
MX380191B true MX380191B (es) 2025-03-12

Family

ID=49785671

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000238A MX380191B (es) 2012-06-27 2013-06-27 Combinaciones de modalidades para el tratamiento de la diabetes.

Country Status (12)

Country Link
US (5) US8735359B2 (es)
EP (1) EP2892548A4 (es)
JP (1) JP6552106B2 (es)
KR (3) KR20200142600A (es)
CN (2) CN104507490A (es)
AU (2) AU2013284469A1 (es)
CA (1) CA2877906C (es)
HK (1) HK1212253A1 (es)
IN (1) IN2015DN00215A (es)
MX (1) MX380191B (es)
WO (1) WO2014004866A1 (es)
ZA (1) ZA201500229B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
WO2014004857A1 (en) 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
SI3151853T1 (sl) * 2014-06-04 2020-10-30 Diamyd Medical Ab Dekarboksilaza glutaminske kisline (GAD) za uporabo v zdravljenju avtoimunske bolezni
US12551459B2 (en) 2014-09-26 2026-02-17 The University Of British Columbia Combination of kynurenine and antigen presenting cells (APC) as therapeutics and methods for their use in immune modulation
GB201504297D0 (en) * 2015-03-13 2015-04-29 Univ London Queen Mary Diagnosis
EP3274053A4 (en) * 2015-03-23 2018-12-05 The Brigham and Women's Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
CN106632684A (zh) * 2016-06-01 2017-05-10 上海领潮生物科技有限公司 一种用于快速检测ⅰ型糖尿病的融合蛋白
DE102017123721A1 (de) 2017-10-12 2019-04-18 Kraussmaffei Technologies Gmbh Verfahren zur Herstellung von faserverstärkten Kunststoff-Formteilen
EP3829557A1 (en) * 2018-08-03 2021-06-09 Institut National De La Sante Et De La Recherche Medicale - Inserm Biocompatible tolerogenic nanoparticles
BR112022009934A2 (pt) * 2019-11-22 2022-08-09 Univ New York State Res Found Método para prevenir ou tratar diabetes tipo 1, e, composição compreendendo lipossomas
CN114377117B (zh) * 2021-12-06 2023-11-10 中国医学科学院医学生物学研究所 一种口服1型糖尿病疫苗及其制备方法
CN119517308B (zh) * 2024-11-06 2025-09-23 西湖大学 用于个性化糖代谢敏感性的量化评估方法及个性化膳食碳水推荐摄入系统

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
KR100238712B1 (ko) 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
ES2114183T5 (es) * 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
US6110746A (en) 1995-06-30 2000-08-29 Yeda Research And Development Co. Ltd. Peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
US7041634B2 (en) 1995-09-27 2006-05-09 Emory University Method of inhibiting immune system destruction of transplanted viable cells
EP0781559B1 (en) 1995-11-30 2007-02-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Oil adjuvant vaccine and method for preparing same
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6797269B2 (en) * 1998-04-03 2004-09-28 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
CN101255192A (zh) 2000-05-26 2008-09-03 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变体分子及其应用
HRP20030071B1 (hr) 2000-07-03 2014-01-03 Bristol-Myers Squibb Company Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
WO2002053106A2 (en) 2001-01-05 2002-07-11 Joslin Diabetes Center, Inc. Autoantigen composition
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
EP1440084B1 (en) * 2001-10-24 2010-01-06 University College Cardiff Consultants Ltd. Sperm factor sequences
US20040136998A1 (en) 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
WO2005076965A2 (en) * 2004-02-04 2005-08-25 The Trustees Of Columbia University In The City Of New York Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity
US8278420B2 (en) 2005-08-06 2012-10-02 Qinghua Wang Composition and method for prevention and treatment of type I diabetes
WO2007127787A2 (en) * 2006-04-25 2007-11-08 Joslin Diabetes Center, Inc. Insulin autoantigen-specific regulatory cd4+ t cells
CN101646418B (zh) * 2006-10-12 2013-07-17 昆士兰大学 调节免疫应答的组合物和方法
WO2009029847A1 (en) * 2007-08-30 2009-03-05 Curedm, Inc. Compositions and methods of using proislet peptides and analogs thereof
US9176122B2 (en) 2008-03-24 2015-11-03 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP2588123A2 (en) 2010-06-30 2013-05-08 Compugen Ltd. C1orf32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
WO2012015903A1 (en) 2010-07-27 2012-02-02 Bayhill Therapeutics, Inc. Treatment of type i diabetes mellitus (t1dm) in young newly diagnosed patients
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US20130316375A1 (en) 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
WO2014004857A1 (en) * 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes

Also Published As

Publication number Publication date
CN113577256A (zh) 2021-11-02
HK1212253A1 (en) 2016-06-10
KR20200142600A (ko) 2020-12-22
JP2015522027A (ja) 2015-08-03
US20240058442A1 (en) 2024-02-22
ZA201500229B (en) 2015-12-23
EP2892548A1 (en) 2015-07-15
US20140220015A1 (en) 2014-08-07
WO2014004866A1 (en) 2014-01-03
US8735359B2 (en) 2014-05-27
CA2877906A1 (en) 2014-01-03
AU2018202802A1 (en) 2018-05-17
KR20220035146A (ko) 2022-03-21
US20190151445A1 (en) 2019-05-23
US20130315904A1 (en) 2013-11-28
AU2013284469A1 (en) 2015-01-29
EP2892548A4 (en) 2016-05-25
CN104507490A (zh) 2015-04-08
IN2015DN00215A (es) 2015-06-12
MX2015000238A (es) 2015-08-14
KR20150036236A (ko) 2015-04-07
JP6552106B2 (ja) 2019-07-31
US20200268883A1 (en) 2020-08-27
AU2018202802B2 (en) 2020-04-02
CA2877906C (en) 2021-01-26

Similar Documents

Publication Publication Date Title
MX380191B (es) Combinaciones de modalidades para el tratamiento de la diabetes.
CL2019002056A1 (es) Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650)
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201692530A1 (ru) Цитотоксические пептиды и их конъюгаты
MX377570B (es) Proteínas de fusión ctla4 para el tratamiento de la diabetes.
BR112017019300A2 (pt) conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
PE20190353A1 (es) Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
AR087715A1 (es) Anticuerpos anti pcsk9 y usos de los mismos
CR20140029A (es) Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada
EA202090683A2 (ru) Способы и композиции для лечения рака
GT201300186A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
BR112016027893A2 (pt) molécula de ligação triespecífica, e, composição farmacêutica
AR074219A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
MX362456B (es) Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
BR112014012878A8 (pt) composto, uso de um composto, composição farmacêutica e processos de fabricação de um composto
AR101740A1 (es) Terapia de combinación y composiciones
BR112016012666A2 (pt) conjugado, anticorpos, formulação farmacêutica e usos de conjugado
PE20091655A1 (es) Farmaco para el cancer de higado
BR112014022780A8 (pt) composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido